Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.

Florinda A SantosRui Manuel ReisLucas C BarrotiAllan A L PereiraMarcus M MatsushitaAna Carolina de CarvalhoJosé Guilherme DatorreGustavo N BerardinelliRaphael Leonardo Cunha de Araujo

Published in: Journal of gastrointestinal cancer (2023)

Although BRAF, NRAS mutations, and MSI-High status were associated with shorter OS in univariate analyses, only tumour laterality remained an independent prognostic factor in the multivariate analysis.

Keyphrases

metastatic colorectal cancer
prognostic factors
wild type
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
locally advanced
squamous cell carcinoma
radiation therapy
data analysis
free survival